BioCentury
ARTICLE | Clinical News

KNS-760704: Additional Phase II data

December 21, 2009 8:00 AM UTC

Additional data from 102 patients in Part 1 of a double-blind, placebo-controlled, U.S. Phase II trial showed that 50, 100 and 300 mg KNS-760704 for 12 weeks displayed a dose-dependent trend in slowing the rate of disease progression as measured by the ALS function rating scale-revised (ALSFRS-R). In 92 patients in Part 2 of the trial, 50 and 300 mg KNS-760704 for an additional 24 weeks showed a trend toward a survival benefit in the 300 mg group compared with the 50 mg group. KNS-760704 was well tolerated. Data were presented at the International Symposium on ALS/MND meeting in Berlin. ...